VanEck Biotech ETF (NASDAQ:BBH) Short Interest Down 16.5% in December

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 18,491 shares, a decline of 16.5% from the November 30th total of 22,133 shares. Based on an average trading volume of 7,132 shares, the short-interest ratio is presently 2.6 days. Currently, 0.9% of the shares of the company are sold short. Currently, 0.9% of the shares of the company are sold short. Based on an average trading volume of 7,132 shares, the short-interest ratio is presently 2.6 days.

VanEck Biotech ETF Trading Down 0.8%

Shares of BBH stock opened at $190.01 on Wednesday. VanEck Biotech ETF has a 12 month low of $135.34 and a 12 month high of $198.08. The stock has a 50 day moving average of $188.40 and a two-hundred day moving average of $172.40.

VanEck Biotech ETF Dividend Announcement

The company also recently announced an annual dividend, which was paid on Friday, December 26th. Investors of record on Monday, December 22nd were given a $0.9565 dividend. This represents a yield of 50.0%. The ex-dividend date of this dividend was Monday, December 22nd.

Institutional Investors Weigh In On VanEck Biotech ETF

Several institutional investors and hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC raised its stake in shares of VanEck Biotech ETF by 66.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 201 shares of the company’s stock valued at $33,000 after buying an additional 80 shares in the last quarter. Caldwell Trust Co bought a new stake in VanEck Biotech ETF in the second quarter valued at about $34,000. Ameritas Advisory Services LLC acquired a new position in VanEck Biotech ETF in the second quarter worth about $57,000. Strategic Financial Services Inc. bought a new position in VanEck Biotech ETF during the first quarter worth about $203,000. Finally, Cibc World Market Inc. bought a new position in VanEck Biotech ETF during the third quarter worth about $204,000. Institutional investors own 32.05% of the company’s stock.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.